Medically reviewed by Dr. Jaramillo, a doctor at Goodweigh. Last updated on 16 October 2026
Short answer from Dr. Jaramillo
Mounjaro or Ozempic: in a head-to-head comparison, Mounjaro resulted in greater weight loss than semaglutide, the active ingredient in Ozempic and Wegovy, in people with obesity who do not have diabetes. Ozempic is intended for diabetes, whilst Wegovy is the semaglutide-based medicine for weight management. The side effects are very similar, and your doctor will work with you to decide which medicine is right for you.
Dr. Jaramillo, doctor at Goodweigh
Want to find out more? Start your intake here
Anyone looking to lose weight with medication will soon find themselves asking: Mounjaro or Ozempic? The short answer is that, in a direct comparison, Mounjaro resulted in greater weight loss, but this may not necessarily be the best choice for everyone. Below, you can read about what these medicines have in common, how they differ, and what to look out for when making your choice. We’ve also included Wegovy and the Wegovy tablet, as people searching for Ozempic often mean weight loss.
What is the difference between Mounjaro and Ozempic?
The main difference is the active ingredient: Mounjaro contains tirzepatide, whilst Ozempic contains semaglutide. Both are injected under the skin once a week.
Semaglutide mimics the hormone GLP-1. This causes your stomach to empty more slowly, so you feel less hungry. Tirzepatide mimics not only GLP-1 but also the hormone GIP, as described in a review article in Cardiovascular Diabetology. Whether this explains the difference in weight loss has not been demonstrated.
The second difference concerns the marketing authorisation. Ozempic is intended for adults with type 2 diabetes. For weight management, the same semaglutide is available under the name Wegovy, with its own patient information leaflet. Read more in ‘Is Ozempic the same as Wegovy?’ Mounjaro covers both indications under a single name: type 2 diabetes and weight management. So, if you’re comparing Mounjaro with semaglutide for weight loss, you’re actually comparing Mounjaro with Wegovy.
Which medicine leads to greater weight loss?
In people without diabetes, Mounjaro resulted in greater weight loss than semaglutide in a head-to-head comparison. In a direct comparison (SURMOUNT-5, New England Journal of Medicine), people taking tirzepatide lost an average of 20.2% of their weight after nearly one and a half years. With semaglutide, the figure was 13.7%. Their waist circumference also decreased more significantly. More people on tirzepatide lost a tenth, a fifth or even a quarter of their weight.
The study does, however, have limitations. It involved 751 people with obesity but without diabetes, who were given the highest dose they could tolerate, and the study was funded by the manufacturer, Eli Lilly. The findings therefore do not automatically apply to people with type 2 diabetes, to lower doses or to the standard titration schedule for Ozempic. How much weight you lose varies greatly from person to person.
Comparison of Mounjaro, Ozempic, Wegovy and the Wegovy tablet
The table compares the treatments side by side. The weight figures are taken from separate studies involving different participants and of different durations, so do not compare them with one another. Only SURMOUNT-5 directly compares Mounjaro with semaglutide in people without diabetes.
What is Wegovy and what is the Wegovy tablet?
Wegovy is Ozempic for weight management: the same active ingredient, a separate brand name and a separate indication. In the STEP 8 study, people taking Wegovy lost an average of 15.8% of their body weight after 68 weeks. This figure comes from a different study to SURMOUNT-5. Please also read about the side effects of Wegovy.
The Wegovy tablet contains semaglutide. According to the European Medicines Agency (EMA), you should take it once a day on an empty stomach, as an alternative to the injection. You can find out whether and when it is available on the Wegovy tablet page. You can read more about the tablet in ‘Wegovy tablet: oral semaglutide’. There is no direct comparison between the tablet and Mounjaro, so we do not provide any figures for this.
How do the dosage and titration differ between GLP-1 medicines?
With all injections, you start with a low dose and build it up gradually so that your body gets used to the medicine. With Mounjaro, you start with 2.5 mg per week, followed by a higher dose after four weeks. The dose can then be increased in stages, up to a maximum of 15 mg.
With Wegovy, you start on a low dose and it takes around 16 weeks to reach the maintenance dose of 2.4 mg.
With Ozempic, the starting dose of 0.25 mg is not the maintenance dose, and the maximum dose is 2 mg.
With Goodweigh, you gradually build up the dose; with Wegovy and Mounjaro, this takes 16 to 20 weeks, and a doctor monitors your symptoms. That pace isn’t the same for everyone.
Which medicine causes the most side effects?
The side effects are very similar. According to the Farmacotherapeutisch Kompas, nausea, vomiting, diarrhoea and constipation are common with semaglutide and tirzepatide, affecting more than 1 in 10 users. In the SURMOUNT-5 trial, gastrointestinal symptoms were the most common in both groups, usually mild to moderate in severity and occurring mainly during dose escalation.
With Mounjaro, nausea, vomiting and diarrhoea tend to subside over time. Drink plenty of fluids during acute episodes of vomiting or diarrhoea to prevent dehydration. Contact your doctor immediately if you experience severe, persistent abdominal pain that radiates to the back. This may be a sign of acute pancreatitis (inflammation of the pancreas). Extra caution is advised if you have a history of pancreatic disorders. Hair loss is listed in the patient information leaflets as a possible side effect following significant weight loss. Rare events such as NAION (non-arteritic anterior ischaemic optic neuropathy) are mentioned in the literature on semaglutide: seek immediate medical attention if you experience sudden changes in your vision. You can read more about this under the side effects of tirzepatide.
What do you need to know about contraception and pregnancy whilst taking GLP-1 medication?
If you could become pregnant, you should use contraception whilst taking any of these three medicines. If you are trying to conceive or are already pregnant, please discuss this with your doctor first.
Please note regarding Mounjaro: the contraceptive pill may be absorbed less effectively after a single dose, although the patient information leaflet states that this is not clinically relevant. Our doctors nevertheless advise using a condom for up to four weeks after each dose increase.
How much does Mounjaro cost compared to Ozempic, and can you switch?
We do not comment on the price here, as it varies depending on the period and the dose. For more information, see ‘Weight-loss medication: price and effectiveness’ or the product page. If you wish to switch from Ozempic to Mounjaro, a doctor will assess this. There is no fixed conversion between the doses, so do not switch on your own initiative.
Would you like to see all the options, including those other than Mounjaro and semaglutide? Then read our comparison of alternatives to Ozempic.
Mounjaro, Wegovy or Ozempic: which one is right for you?
That depends on your health, your goal, how well you tolerate the medication and what you’re able to take. If you have type 2 diabetes, could become pregnant, or have previously had pancreatitis, your doctor will take these factors into account. Greater weight loss in a trial does not necessarily mean that Mounjaro is better for you.
At Goodweigh, you complete an online intake. A doctor will review your details and discuss with you which medication is suitable. You can start your online intake whenever you’re ready.
Quellen
Aronne, L. J., Horn, D. B., le Roux, C. W., Ho, W., Falcon, B. L., Gomez Valderas, E., ... Dunn, J. P. (2025). Tirzepatide as compared with semaglutide for the treatment of obesity. New England Journal of Medicine, 393(1), 26-36. https://pubmed.ncbi.nlm.nih.gov/40353578/
Rubino, D. M., et al. (2022). Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial. JAMA, 327(2), 138-150. https://pubmed.ncbi.nlm.nih.gov/35015037/
Nauck, M. A., & D'Alessio, D. A. (2022). Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovascular Diabetology, 21, 169. https://pubmed.ncbi.nlm.nih.gov/36050763/
Europees Geneesmiddelenbureau. Mounjaro: productinformatie. https://www.ema.europa.eu/nl/documents/product-information/mounjaro-epar-product-information_nl.pdf
Europees Geneesmiddelenbureau. Ozempic: productinformatie. https://www.ema.europa.eu/nl/documents/product-information/ozempic-epar-product-information_nl.pdf
Europees Geneesmiddelenbureau. Wegovy: productinformatie. https://www.ema.europa.eu/nl/documents/product-information/wegovy-epar-product-information_nl.pdf
Europees Geneesmiddelenbureau. First oral GLP-1 treatment for weight management. https://www.ema.europa.eu/en/news/first-oral-glp-1-treatment-weight-management
Frequently Asked Questions
In the direct comparison with SURMOUNT-5, people taking Mounjaro lost more weight on average than those taking semaglutide, the active ingredient in Ozempic and Wegovy. Whether it is better for you depends on your individual circumstances. A doctor will decide this together with you.
No. Mounjaro contains tirzepatide and Ozempic contains semaglutide. Mounjaro is available for type 2 diabetes and weight management under a single brand name, whilst Ozempic is only for diabetes.
Wegovy and Ozempic both contain semaglutide. They are two brands, each with its own indication: Ozempic for type 2 diabetes, Wegovy for weight management.
That is not yet known. You can find the latest information on the Wegovy tablet page.
A doctor will assess this. There is no fixed conversion table for the doses, so do not switch yourself. Discuss your symptoms and goals first.



